Navigation Links
JDRF and Lilly partner to fund research to identify beta cell biomarkers
Date:11/14/2007

NEW YORK, NY November 14, 2007 The Juvenile Diabetes Research Foundation and Eli Lilly and Company announced today that they are joining together to create a $3 million research effort to accelerate the pace of research into drugs and therapies to cure diabetes and its complications by developing biomarkers indicators that can measure the progress of disease and the effectiveness of therapeutics.

The project -- called the JDRF-Lilly Innovative and Academic Research and Development Grants in Diabetes Biomarkers will be funded by a $3 million grant from the Lilly Foundation to JDRF over three years.

JDRF is the world's largest charitable funder of type 1 diabetes research; over the last year, JDRF has funded more than $137 million in research to cure and develop therapeutics for type 1 diabetes and its complications. Lilly is a global leader in diabetes science and treatment, dating back to the development of the world's first commercially-available insulin in the 1920s, and continues to pioneer research to develop innovative medicines to address the unmet needs of people with diabetes.

The new JDRF-Lilly project will support cutting-edge research on biomarkers for pancreatic beta cell mass and function.

Biomarkers are natural features (lab values, images, or clinical features) whose detection indicates the presence of a particular disease state, or correlates with the risk or progression of a disease; for example, elevated prostate specific antigen is a molecular biomarker for prostate cancer. Two of the best-known biomarkers are cholesterol and blood pressure levels, which denote key information about cardiovascular health. In evaluating potential therapeutics, biomarkers can also serve as surrogate endpoints for evaluating the clinical benefit of a treatment.

In general, the development of a range of biomarkers for both diabetes itself and its various complications would fill a major gap in science leading to a cure, said Arnold W. Donald, President and Chief Executive Officer of JDRF. As the field of diabetes research moves from purely discovery research to the development of therapeutic cures and treatments, biomarkers will play a key role in increasing the pace of progress, and providing real benefits to people with diabetes. Lillys grant to support beta cell mass and function research will play an important role in these efforts.

According to Dr. Paul Burn, Senior Vice President, Research, at JDRF, there are few current biomarkers for type 1 diabetes research and treatment. Biomarkers would be a powerful research tool in indicating the onset, status, and stage of diabetes; in predicting and monitoring a patients clinical response to treatments developed as part of research funded by JDRF, Lilly, and others; and in accelerating the development of therapeutics by enabling researchers to rapidly assess the clinical outcomes of promising drug candidates.

Biomarkers and the comprehensive information they can provide researchers are imperative to the progress of diabetes research, Dr. Burn said. This project can rapidly advance the pace of scientific discovery and therapeutic developments for type 1 diabetes patients along multiple research pathways to finding a cure. Lilly is making a tremendous contribution to science that could, in turn, significantly improve the lives and outlooks of millions.

Lillys highest mission is to improve the lives of the people we serve and there is no group of patients with whom we have a longer and deeper relationship than people with diabetes, said Dr. John C. Lechleiter, Lillys President and Chief Operating Officer. Until theres a cure for diabetes, its imperative that we continue searching for ways to improve treatment and solutions for managing this condition and its devastating complications. This research by JDRF could provide breakthroughs that would move the treatment of diabetes forward in new and exciting directions and maybe one day lead to a cure, the ultimate goal of diabetes research.

Grants by the JDRF-Lilly project will be available to both academic and commercial investigators. Innovative grant proposals will be evaluated through JDRFs grant review process, which includes both peer scientific review and lay review committees. For Academic Research and Development grants, JDRF will look to proactively match academic researchers with specific scientific targets. Currently, JDRF reviews thousands of research proposals annually, and funds more than 700 discovery and development projects.


'/>"/>

Contact: Susan Sherman
ssherman@jdrf.org
212-479-7510
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: